Dean Capital Management Increases Position in Prestige Consumer Healthcare Inc. $PBH

Dean Capital Management grew its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 65.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 67,798 shares of the company’s stock after buying an additional 26,899 shares during the period. Prestige Consumer Healthcare makes up 1.7% of Dean Capital Management’s portfolio, making the stock its 5th largest position. Dean Capital Management’s holdings in Prestige Consumer Healthcare were worth $4,018,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Rice Hall James & Associates LLC raised its position in shares of Prestige Consumer Healthcare by 4.2% during the first quarter. Rice Hall James & Associates LLC now owns 521,622 shares of the company’s stock worth $30,917,000 after purchasing an additional 21,022 shares during the period. Wealth Alliance LLC acquired a new position in shares of Prestige Consumer Healthcare in the 1st quarter valued at approximately $250,000. Morningstar Investment Management LLC increased its stake in Prestige Consumer Healthcare by 118.0% during the 1st quarter. Morningstar Investment Management LLC now owns 33,410 shares of the company’s stock worth $1,980,000 after purchasing an additional 18,082 shares in the last quarter. Inceptionr LLC bought a new stake in Prestige Consumer Healthcare during the 1st quarter worth approximately $433,000. Finally, Gibbs Wealth Management bought a new stake in Prestige Consumer Healthcare during the 1st quarter worth approximately $568,000. Institutional investors own 99.95% of the company’s stock.

Insider Transactions at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares in the company, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.50% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Stock Up 0.0%

Prestige Consumer Healthcare stock opened at $49.67 on Monday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. The company’s 50-day moving average is $47.94 and its 200-day moving average is $56.87. The firm has a market capitalization of $2.35 billion, a PE ratio of 12.70, a P/E/G ratio of 1.60 and a beta of 0.35. Prestige Consumer Healthcare Inc. has a fifty-two week low of $42.62 and a fifty-two week high of $77.03.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The company had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. During the same quarter in the prior year, the firm earned $1.32 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

PBH has been the topic of a number of research reports. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Finally, Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).